Gilead Sciences Inc. shares declined in the extended session Tuesday after the biotech company's quarterly earnings fell short of Wall Street estimates. Gilead shares fell 3.2% to $66.39 after hours, following a 0.7% gain in the regular session. The company reported adjusted first-quarter earnings of $2.23 a share on revenue of $6.51 billion. Analysts surveyed by FactSet had forecast earnings of $2.28 a share on revenue of $6.63 billion. Gilead reiterated its outlook for the year of revenue of $22.5 billion to $24.5 billion, which excludes royalty revenue. Analysts expect total revenue of $24.73 billion.
Copyright © 2017 MarketWatch, Inc.
Continue Reading Below